Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: J Thromb Haemost. 2022 Dec 22;21(3):522–533. doi: 10.1016/j.jtha.2022.10.027

Figure 3. Fibrinogen synthesis is decreased by siRNAs targeting the fibrinogen structural genes.

Figure 3.

(A) HepG2 cells were treated with siRNAs for 48 hours and then incubated in reduced serum media (RSM) in the (B-D) absence or (E-G) presence of IL-6 for 24 hours. Effects on fibrinogen (B, E) gene expression, (C, F) protein production, and (D, G) cell viability were assessed by immunoblotting, RT-qPCR, and cell counts, respectively. All data were normalized to treatment with control siRNA (siNC), N=3–12 for each siRNA, bars indicate mean + standard error of the mean, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001